Grifols (GRFS) Total Current Liabilities (2009 - 2025)
Grifols' (GRFS) quarterly Total Current Liabilities came in at $2.4 billion in Q4 2025, up 2.01% YoY from $2.3 billion in Q4 2024, and up 2.01% on a QoQ basis from $2.3 billion in Q4 2024.
Grifols (GRFS) Total Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Total Current Liabilities data on file, last reported at $2.4 billion in Q4 2025.
- Quarterly Total Current Liabilities rose 2.01% year-over-year to $2.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 billion (up 2.01% YoY) and the FY2025 annual result came in at $2.4 billion, up 4900.43% from the prior year.
- Total Current Liabilities rose to $2.4 billion in Q4 2025, from $2.3 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $4.0 billion in Q4 2021 to a low of $2.1 billion in Q4 2022.
- A 5-year average of $2.6 billion and a median of $2.4 billion in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 149.68% — and 2022, when it sank 48.17%.
- Tracing GRFS's Total Current Liabilities over 5 years: stood at $4.0 billion in 2021, then slumped by 48.17% to $2.1 billion in 2022, then climbed by 21.45% to $2.5 billion in 2023, then fell by 7.92% to $2.3 billion in 2024, then gained by 2.01% to $2.4 billion in 2025.
- The last three Total Current Liabilities figures came in at $2.4 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.5 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Grifols | 5.46 Bn | 4.46 Bn | - | 2.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | 2.30 Bn |
| Dec 31, 2023 | 2.50 Bn |
| Dec 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Dec 31, 2020 | 1.59 Bn |
| Sep 30, 2020 | 1.45 Bn |
| Mar 31, 2020 | 1.47 Bn |
| Dec 31, 2019 | 1.51 Bn |
| Sep 30, 2019 | 1.55 Bn |
| Dec 31, 2018 | 1.44 Bn |
| Sep 30, 2018 | 1.26 Bn |
| Jun 30, 2018 | 1.21 Bn |
| Mar 31, 2018 | 1.49 Bn |
| Dec 31, 2017 | 1.15 Bn |
| Jun 30, 2017 | 989.95 Mn |
| Dec 31, 2016 | 1.16 Bn |
| Sep 30, 2016 | 1.03 Bn |
| Jun 30, 2016 | 1.10 Bn |
| Dec 31, 2015 | 1.15 Bn |